Abstract
To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P
| Original language | English |
|---|---|
| Pages (from-to) | 335-338 |
| Number of pages | 4 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 1987 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research
Cite this
A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. / Pollera, Camillo F.; Nardi, Mario; Marolla, Paolo; Carlini, Paolo.
In: Cancer Chemotherapy and Pharmacology, Vol. 19, No. 4, 07.1987, p. 335-338.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin
AU - Pollera, Camillo F.
AU - Nardi, Mario
AU - Marolla, Paolo
AU - Carlini, Paolo
PY - 1987/7
Y1 - 1987/7
N2 - To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P
AB - To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P
UR - http://www.scopus.com/inward/record.url?scp=0023186763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023186763&partnerID=8YFLogxK
U2 - 10.1007/BF00261484
DO - 10.1007/BF00261484
M3 - Article
C2 - 3297376
AN - SCOPUS:0023186763
VL - 19
SP - 335
EP - 338
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 4
ER -